Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Ocular Therapeutix, Inc is a biotechnology business based in the US. Ocular Therapeutix shares (OCUL) are listed on the NASDAQ and all prices are listed in US Dollars. Ocular Therapeutix employs 161 staff and has a trailing 12-month revenue of around USD$12.3 million.
Since the stock market crash in March caused by coronavirus, Ocular Therapeutix's share price has had significant positive movement.
Its last market close was USD$13.78, which is 59.00% up on its pre-crash value of USD$5.65 and 265.03% up on the lowest point reached during the March crash when the shares fell as low as USD$3.775.
If you had bought USD$1,000 worth of Ocular Therapeutix shares at the start of February 2020, those shares would have been worth USD$1,066.38 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$3,048.69.
|Latest market close||USD$13.78|
|52-week range||USD$2.92 - USD$14.16|
|50-day moving average||USD$10.9168|
|200-day moving average||USD$8.6974|
|Wall St. target price||USD$14.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.79|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-16)||13.78|
|1 month (2020-10-26)||41.62%|
|3 months (2020-08-24)||70.97%|
|6 months (2020-05-22)||90.86%|
|1 year (2019-11-22)||334.70%|
|2 years (2018-11-23)||142.61%|
|3 years (2017-11-24)||232.05%|
|5 years (2015-11-24)||57.67%|
|Revenue TTM||USD$12.3 million|
|Gross profit TTM||USD$-39,189,000|
|Return on assets TTM||-46.75%|
|Return on equity TTM||-2677.1%|
|Market capitalisation||USD$964.5 million|
TTM: trailing 12 months
There are currently 6.2 million Ocular Therapeutix shares held short by investors – that's known as Ocular Therapeutix's "short interest". This figure is 11.2% down from 6.9 million last month.
There are a few different ways that this level of interest in shorting Ocular Therapeutix shares can be evaluated.
Ocular Therapeutix's "short interest ratio" (SIR) is the quantity of Ocular Therapeutix shares currently shorted divided by the average quantity of Ocular Therapeutix shares traded daily (recently around 1.6 million). Ocular Therapeutix's SIR currently stands at 3.77. In other words for every 100,000 Ocular Therapeutix shares traded daily on the market, roughly 3770 shares are currently held short.
However Ocular Therapeutix's short interest can also be evaluated against the total number of Ocular Therapeutix shares, or, against the total number of tradable Ocular Therapeutix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocular Therapeutix's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Ocular Therapeutix shares in existence, roughly 90 shares are currently held short) or 0.0969% of the tradable shares (for every 100,000 tradable Ocular Therapeutix shares, roughly 97 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ocular Therapeutix.
Find out more about how you can short Ocular Therapeutix stock.
We're not expecting Ocular Therapeutix to pay a dividend over the next 12 months.
Over the last 12 months, Ocular Therapeutix's shares have ranged in value from as little as $2.92 up to $14.16. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocular Therapeutix's is 1.6979. This would suggest that Ocular Therapeutix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert), which has completed two Phase III clinical trials for the treatment of post-surgical ocular pain and inflammation, and allergic conjunctivitis; and DEXTENZA, which is in Phase III clinical trials for the treatment of dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert), which is in Phase III clinical trials for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant, which is in Phase I clinical trials for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant, which is in Phase I clinical trials for the treatment of wet age-related macular degeneration(AMD). Its various preclinical programs include OTX- BPI for the treatment of acute ocular pain; OTX-BDI to treat post-operative Pain, and inflammation and bacterial infection; OTX-CSI to treat dry-eye disease; and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.